PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Sherief Abd-Elsalam

Status and phase: Enrolling; Phase 3

Conditions: Lymphoma

Treatments: Drug: CHOP Plus Lanzoprazole; Drug: CHOP Plus Famotidine; Drug: CHOP

Study type: Interventional

Funder types: Other

Identifiers

NCT03647072

eman elberry

Details and patient eligibility

About

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Full description

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump Inhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma to compare the difference in efficacy.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• DLBCL Lymphoma subtype --No comorbid disease

Exclusion criteria

• Pregnancy
• Peptic ulcer
• Severe cardiac disease
• Osteoporosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 3 patient groups

CHOP

Active Comparator group

Description:

CHOP only

Treatment:

Drug: CHOP

CHOP Plus Lanzoprazole

Active Comparator group

Description:

CHOP Plus Lanzoprazole 60 mg

Treatment:

Drug: CHOP Plus Lanzoprazole

CHOP Plus Famotidine

Active Comparator group

Description:

CHOP Plus Famotidine 40 mg

Treatment:

Drug: CHOP Plus Famotidine